The Motley Fool··Seena HassounaImmunome Insider Sale Masks Real Story: FDA Filing Looms for Varegacestat
Immunome's Chief Scientific Officer trimmed his stake by 30%, but the real catalyst is varegacestat's planned Q2 2026 FDA submission following positive Phase 3 trial results.
IMNMPhase 3 trialNDA submission